Literature DB >> 708010

Pharmacology of intraperitoneal cefazolin in patients undergoing peritoneal dialysis.

D Kaye, N Wenger, B Agarwal.   

Abstract

Cefazolin was added to dialysis fluid in nine patients with renal failure undergoing peritoneal dialysis with 2 liters/h per exchange. With 50 mg/liter (three patients), the first measurable mean serum concentration was 3.7 mug/ml (range, 2.4 to 4.9 mug/ml) after three exchanges and was 30.3 mug/ml (range, 13.3 to 44.3 mug/ml) after 24 exchanges. After 18 to 24 more exchanges without cefazolin, the mean serum concentration was 12.3 mug/ml (range, 3.8 to 24.6 mug/ml). The mean concentration in the dialysis outflow was 26.9 mug/ml (range, 2.5 to 58.5 mug/ml). With 150 mg/liter (six patients), the mean serum concentration was 5.2 mug/ml (range, 3.6 to 7.8 mug/ml) after the first exchange and 8.4 (range, 6.1 to 14.0 mug/ml), 15.0 (range, 8.2 to 23.5 mug/ml), and 71.9 (range, 26.2 to 142.1 mug/ml) mug/ml after the second, third, and twenty-fourth exchanges, respectively. After 17 to 24 more exchanges without cefazolin, the mean serum concentration was 38.2 mug/ml (range, 15.4 to 65.7 mug/ml). The mean concentration in the dialysis outflow was 71.4 mug/ml (range, 21.9 to 150.8 mug/ml). After 1 g of cefazolin was given intraperitoneally with no more dialysis, serum concentrations rose by a mean of 62.5 mug/ml (range, 18.9 to 107.8 mug/ml). The maximum rise occurred within 2 h with two-thirds of the rise occurring within 30 min. During the subsequent 22 h levels dropped to 65.4% of the peak.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 708010      PMCID: PMC352457          DOI: 10.1128/AAC.14.3.318

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Effects of renal failure and dialysis on cefazolin pharmacokinetics.

Authors:  T Madhavan; K Yaremchuk; N Levin; E Fisher; F Cox; K Burch; E Haas; D Pohlod; E L Quinn
Journal:  Antimicrob Agents Chemother       Date:  1975-07       Impact factor: 5.191

2.  Prolonged antibiotic peritoneal lavage in the management of gross generalized peritonitis.

Authors:  R C Atkins; D F Scott; S R Holdsworth; A J Davidson
Journal:  Med J Aust       Date:  1976-06-19       Impact factor: 7.738

3.  Prophylaxis with cephalothin in peritoneal dialysis.

Authors:  J Axelrod; B R Meyers; S Z Hirschman; R Stein
Journal:  Arch Intern Med       Date:  1973-09

4.  Pharmacokinetics of cefazolin in normal and uremic subjects.

Authors:  P G Welling; W A Craig; A L Gordon; C M Kunin
Journal:  Clin Pharmacol Ther       Date:  1974-04       Impact factor: 6.875

5.  Pharmacology of cefazolin in patients with normal and abnormal renal function.

Authors:  M E Levison; S P Levison; K Ries; D Kaye
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

6.  Irrigation of the peritoneal cavity with cephalothin.

Authors:  W M Rambo
Journal:  Am J Surg       Date:  1972-02       Impact factor: 2.565

7.  The passage of cephalothin into and out of ascitic fluid.

Authors:  D E Wilson; T C Chalmers; M A Madoff
Journal:  Am J Med Sci       Date:  1967-04       Impact factor: 2.378

8.  Pharmacodynamics of cefazolin in the presence of normal and impaired renal function.

Authors:  M F Rein; F B Westervelt; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1973-09       Impact factor: 5.191

9.  Clinical and in vitro evaluation of cefazolin, a new cephalosporin antibiotic.

Authors:  K Ries; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

  9 in total
  2 in total

Review 1.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

2.  Peritoneal absorption of moxalactam.

Authors:  N M Stephens; N O Kronfol; B J Kline; R E Polk
Journal:  Antimicrob Agents Chemother       Date:  1983-07       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.